Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data STANDARD BIOTOOLS INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
104
102
113
117
138
131
97.9
106
91
85.3
Cost of revenue
0.3
50
51.3
53
60.9
55.9
46.1
42.8
Gross profit
58.4
52
61.6
64.3
37.1
50.5
44.9
42.5
Research and development
38.4
30.8
30
31.6
36.5
37.9
37.4
25.9
28.8
26
Selling, general and administrative
93.2
79.5
79.8
84.5
97.9
98.9
102
87.5
103
110
Operating expenses
132
110
161
169
189
198
153
127
172
153
Operating income
-73.2
-58.4
-48.2
-51.8
-51
-67.5
-116
-76.6
-127
-110
Interest expense
5.82
5.82
13.9
4.28
3.57
3.82
4.33
4.57
Other non-operating income
-1.17
0.39
0.64
1.43
0.51
0.48
-0.82
1.39
-5.01
4.39
Pre-tax income
-80.2
-63.8
-61.4
-66.7
-54.1
-63.7
-193
-74.2
-90.4
-96.7
Income tax
-4.19
-3.26
-2.41
-1.92
-1.08
-4.42
-2.83
0.45
0.54
-37.9
Income from continuing operations
-74.7
-90.9
-58.8
Net income
-76
-60.5
-59
-64.8
-53
-59.2
-190
-74.7
-139
-74.9
EBITDA
-66.5
-51
-42.8
-47.2
-47
-64.2
-104
-63.9
-115
-101
EPS, basic
-2.62
-1.84
-1.49
-0.97
-0.74
-0.78
-2.43
-0.94
-0.52
-0.20
EPS, diluted
-2.62
-1.84
-1.49
-0.97
-0.74
-0.78
-2.43
-0.94
-0.52
-0.20
Shares, basic (weighted)
29
33
39.7
66.8
72
75.8
78.3
79.2
353
382
Shares, diluted (weighted)
29
33
39.7
66.8
72
75.8
78.3
79.2
353
382
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
35
58.1
95.4
21.7
68.5
28.5
81.3
51.7
167
121
Short-term investments
24.4
5.08
0
37
0
0
84.5
63.2
126
66.7
Receivables
14.6
15
16.7
19
25.4
18.3
17.3
19.7
14.7
13.4
Inventory
20.1
15.1
13
13.9
19.7
20.8
21.5
20.5
20.7
20
Other current assets
2.52
1.53
2.05
4.59
4.03
4.47
4.28
3.13
4.56
4.87
Total current assets
96.7
94.8
127
96.1
118
72.1
209
158
376
454
Property, plant and equipment
16.5
12.3
8.83
8.06
17.5
28
25.7
24.2
22.8
19.3
Lease right-of-use assets
0
4.86
38.1
37.1
33.9
30.7
26.6
26.7
Goodwill
104
104
104
104
107
106
106
106
111
Intangible assets
79.8
68.6
57.4
46.2
40.2
27.9
12.6
1.4
29
Long-term investments
0
0
25.7
Other non-current assets
9.29
7.54
6.21
5.49
4.68
3.69
3.11
2.29
3.55
3.15
Total assets
306
287
304
265
325
275
390
323
612
568
Accounts payable
3.97
4.21
4.03
5.15
9.22
10.6
7.91
9.24
5.05
5.41
Accrued liabilities
12.4
8.49
7.62
8.87
11.9
8.67
6.18
21
21.4
29.8
Deferred revenue
9.16
10.2
11.5
11.8
13.5
11.9
10.8
11.6
10.3
38.9
Total current liabilities
29.5
33.5
37.6
32.8
54.2
49.6
43.4
109
65.9
108
Lease liabilities
0
4.32
38.2
37.5
34.1
30.4
25.6
25
Other non-current liabilities
3.26
5.83
1.85
0.57
1.33
0.88
0.96
1.07
1.06
1.22
Total liabilities
253
256
232
111
186
181
161
160
141
143
Total debt
195
64.9
63.5
0.3
Paid-in capital
493
532
632
778
816
831
847
861
1,702
1,732
Retained earnings
-439
-500
-559
-624
-677
-736
-926
-1,001
-1,186
-1,261
Treasury stock
0
-0.56
-5.98
-46.5
-46.5
Other comprehensive income
-0.76
-0.57
-0.69
-0.58
0.11
-0.91
-1.9
-2.22
1.23
-1.49
Shareholders' equity
53.2
30.9
72.1
154
139
94.6
-81.5
-148
472
424
Total equity
53.2
30.9
72.1
154
139
94.6
-81.5
-148
472
424
Total liabilities and equity
306
287
304
265
325
275
390
323
612
568
Shares outstanding
29.2
38.8
49.3
70
74.5
76.9
79.5
80.2
378
386
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-76
-60.5
-59
-64.8
-53
-59.2
-190
-74.7
-139
-74.9
Depreciation and amortization
6.74
7.41
5.37
4.61
4.01
3.22
12.5
12.7
12.5
9.26
Stock-based compensation
13.9
9.09
11
11.4
14.5
16.1
14.9
13.1
31.7
29.6
Deferred income tax
-3.92
-3.78
-2.49
-2.51
-3.43
-4.32
-3.32
-0.12
0.21
-38.8
Change in receivables
10.5
-0.55
-1.79
-2.08
-7.63
6.73
1.06
-2.99
8.97
-1.36
Change in inventory
-3.39
4.16
0.4
-3.05
-8.64
-4.78
-8.47
-4.91
-9.88
-11.5
Change in payables
-2.27
0.59
-0.29
0.79
3.36
1.28
-2.78
1.62
-13
2.44
Cash from operations
-39.1
-24.1
-25.2
-35.2
-15.4
-44.1
-89.4
-43.3
-143
-74.3
Capital expenditures
-5.07
-1.57
-0.37
-2.53
-12.7
-13.3
-3.83
-2.83
-8.36
-8.3
Acquisitions
0
0
0
-5.15
0
0
-1.39
0
Purchases of investments
-38.6
-6.28
-1.45
-62.4
0
0
-137
0
0
-6.86
Sales and maturities of investments
86.4
25.6
6.54
25.6
Cash from investing
45.1
17.7
4.72
-39.3
40
-11.9
-88.1
20.2
363
27.4
Debt issued
0
0
55
0
0
Debt repaid
0
0
-51.8
0
-0.5
0
Stock issued
0
28.8
59.5
0
20.2
0
0.1
0.1
1.15
0.53
Share buybacks
0
-0.56
-5.41
-40.5
0
Cash from financing
0.12
29
57.7
2.79
20.9
16
231
-6.81
-103
0.57
Exchange rate effect
-0.15
0.45
0.17
0.06
0.39
-0.02
-0.4
0.03
-0.79
0.84
Net change in cash
5.93
23
37.3
-71.7
45.8
-40.1
52.9
-29.8
116
-45.5
Free cash flow
-44.2
-25.7
-25.6
-37.7
-28.1
-57.3
-93.2
-46.1
-152
-82.6
Interest paid
5.53
5.53
5.53
3.54
3.09
3.15
3.49
3.82
3.09
0.02
Income taxes paid
0.36
0.25
0.32
0.21
0.52
2.09
0.31
0.8
0.61
-0.07
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.74 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
50.5%
Gross profit / revenue.
Operating margin
-112.8%
Operating income / revenue.
EBITDA margin
-106.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-107.5%
Pre-tax income / revenue.
Net margin
100.4%
Net income / revenue.
FCF margin
-97.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-94.9%
Cash from operations / revenue.
Return on equity (ROE)
15.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
13.5%
Net income / average total assets.
Return on invested capital (ROIC)
-27.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
21.8%
Research and development expense / revenue.
SG&A / revenue
102.8%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
30.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.7%
Capital expenditures / revenue.
D&A / revenue
6.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-6.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-4.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-9.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-5.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
4.7%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-10.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y
25.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-7.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
13.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
11.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
8.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
69.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
39.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.10x
Current assets / current liabilities.
Quick ratio
8.67x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.39x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
FCF conversion
-97.3%
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.22
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.22
Revenue / diluted weighted shares.
FCF per share
-$0.21
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.21
Cash from operations / diluted weighted shares.
Book value per share
$1.38
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
3.42x
Market cap / net income. Only when net income is positive.
P/S
3.43x
Market cap / revenue.
P/B
0.54x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.54x
Market cap / tangible book value, when positive.
FCF yield
-28.4%
Free cash flow / market cap.
Earnings yield
29.2%
Net income / market cap (the inverse of P/E).
What was STANDARD BIOTOOLS INC.'s revenue in fiscal 2025?
STANDARD BIOTOOLS INC. reported revenue of $85.3M for fiscal 2025, 6.2% lower than the year before.
Was STANDARD BIOTOOLS INC. profitable in fiscal 2025?
No. It reported a net loss of $74.9M.
How much free cash flow did STANDARD BIOTOOLS INC. generate in fiscal 2025?
Cash from operations of $74.3M minus capital expenditures of $8.3M left free cash flow of -$82.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.